Report: No Mortality Benefit with Routine PSA Screening, Longer-Term Follow-Up Shows
According to a report in the Jan. 9, 2012, “Journal Watch,” screening with prostate-specific
antigen (PSA) testing does not lower the risk for death from prostate cancer, according to a 13-
year follow-up report from the PLCO trial. The abstract for the follow up report was published
in the Journal of the National Cancer Institute. This finding extends the trial's 10-year results,
which similarly showed no mortality benefit.
“Journal Watch” noted that the PLCO trial, some 77,000 men aged 55 to 74 were either
randomly placed in 6 years of PSA testing plus 4 years of digital rectal examinations, or to
usual care (which could include opportunistic screening). “At 13 years' follow-up, there was no
difference between the groups in prostate cancer mortality. The incidence of prostate cancer,
however, was significantly higher with screening than with usual care (108.4 vs. 97.1 per
10,000 person-years),” “Journal Watch” reported.
The researchers conclude: "There is no evidence of a benefit [from screening]. Indeed, there
is evidence of harms, in part associated with the false-positive tests, but also with the over
diagnosis inseparable from PSA screening."
Last Updated on Thursday, 12 January 2012 12:59
[Report] Advises Against Routine Prostate Cancer ScreeningSpeaking Out for WomenMichelle King Robson is the Founder, Chairperson and CEO of www.EmpowHERcom, one of the fastest-growing and largest social health companies dedicated exclusively to women's health and wellness and whose site Vibrance sites partner with. Share your thoughts with Ms. Robson by going to our boards by going to www.empowHER,com or by clicking here for Vibrance forums. |
||||
|
||||
|
More Articles...
|
||||
|
|
||||
| Page 1 of 4 |